Literature DB >> 3515602

Prognostic factors in patients with brain metastases from lung carcinoma.

M Chatani, T Teshima, K Hata, T Inoue.   

Abstract

Between September 1980 to December 1983, 70 consecutive patients were entered into two randomly allocated trials in order to investigate the effectiveness of different time-dose radiotherapy schemes (i.e., 30 Gy/ten fractions/two weeks versus 50 Gy/20 fractions/four weeks) and the prognostic factors on the palliation for patients with brain metastases from lung carcinoma. The most important factors for predicting poor prognosis in this series, which were shown by stepwise proportional hazard (Cox) model, were lactate dehydrogenase (LDH) and general performance status. In normal LDH group, the most important factors for predicting poor prognosis were multiplicity of brain metastases (p less than 0.001), treatment methods (p less than 0.0005) and age (p less than 0.0053). In high LDH group any items were not shown for meeting of the 0.05 significant level.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3515602

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  5 in total

1.  KPS/LDH index: a simple tool for identifying patients with metastatic melanoma who are unlikely to benefit from palliative whole brain radiotherapy.

Authors:  Richard Partl; Gerd Fastner; Julia Kaiser; Elisabeth Kronhuber; Klaudia Cetin-Strohmer; Claudia Steffal; Barbara Böhmer-Breitfelder; Johannes Mayer; Alexander Avian; Andrea Berghold
Journal:  Support Care Cancer       Date:  2015-06-24       Impact factor: 3.603

Review 2.  The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Laurie E Gaspar; Minesh P Mehta; Roy A Patchell; Stuart H Burri; Paula D Robinson; Rachel E Morris; Mario Ammirati; David W Andrews; Anthony L Asher; Charles S Cobbs; Douglas Kondziolka; Mark E Linskey; Jay S Loeffler; Michael McDermott; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Timothy C Ryken; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

Review 3.  Radiotherapy for metastatic brain tumors.

Authors:  Yuta Shibamoto; Chikao Sugie; Hiromitsu Iwata
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

4.  Towards improved prognostic scores predicting survival in patients with brain metastases: a pilot study of serum lactate dehydrogenase levels.

Authors:  Carsten Nieder; Kirsten Marienhagen; Astrid Dalhaug; Jan Norum
Journal:  ScientificWorldJournal       Date:  2012-04-19

Review 5.  Neuropsychological testing and biomarkers in the management of brain metastases.

Authors:  Andrew Baschnagel; Pamela L Wolters; Kevin Camphausen
Journal:  Radiat Oncol       Date:  2008-09-17       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.